Mann S, Frasca K, Scherrer S, et al. A review of leishmaniasis: current knowledge and future directions. Curr Trop Med Rep. 2021;8:121–32. https://doi.org/10.1007/s40475-021-00232-7.

Article  PubMed  PubMed Central  Google Scholar 

Tamiru HF, Mashalla YJ, Mohammed R, Tshweneagae GT. Cutaneous leishmaniasis a neglected tropical disease: community knowledge, attitude and practices in an endemic area Northwest Ethiopia. BMC Infect Dis. 2019;19:855. https://doi.org/10.1186/s12879-019-4506-1.

Article  PubMed  PubMed Central  Google Scholar 

DebRoy S, Prosper O, Mishoe A, Mubayi A. Challenges in modeling complexity of neglected tropical diseases: a review of dynamics of visceral leishmaniasis in resource limited settings. Emerg Themes Epidemiol. 2017;14:10. https://doi.org/10.1186/s12982-017-0065-3.

Article  PubMed  PubMed Central  Google Scholar 

Brindha J, Ballamurali MM, Kaushik C. An overview on the therapeutics of neglected infectious diseases—leishmaniasis and chagas diseases. Front Chem. 2021;9. https://doi.org/10.3389/fchem.2021.622286.

Jain S, Madjou S, Agua JFV, et al. Global leishmaniasis surveillance updates 2023: 3 years of the NTD road map. 2023. https://www.who.int/publications/i/item/who-wer-9945-653-669.

Gurel MS, Tekin B, Uzun S. Cutaneous leishmaniasis: a great imitator. Clin Dermatol. 2020;38:140–51. https://doi.org/10.1016/j.clindermatol.2019.10.008.

Article  PubMed  Google Scholar 

Abadías-Granado I, Diago A, Cerro PA, et al. Cutaneous and mucocutaneous leishmaniasis. Actas Dermo-Sifiliográficas (English edin). 2021;112:601–18. https://doi.org/10.1016/j.adengl.2021.05.011.

Article  Google Scholar 

Strazzulla A, Cocuzza S, Pinzone MR, et al. Mucosal Leishmaniasis: an underestimated presentation of a neglected disease. Biomed Res Int. 2013;1–7. https://doi.org/10.1155/2013/805108

Gupta S, Pal A, Vyas SP. Drug delivery strategies for therapy of visceral leishmaniasis. Expert Opin Drug Deliv. 2010;7:371–402. https://doi.org/10.1517/17425240903548232.

Article  CAS  PubMed  Google Scholar 

Gupta AK, Das S, Kamran M, et al. The pathogenicity and virulence of Leishmania - interplay of virulence factors with host defenses. Virulence. 2022;13:903–35. https://doi.org/10.1080/21505594.2022.2074130.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000Res. 2017;6:750. https://doi.org/10.12688/f1000research.11120.1

de Menezes JPB, Guedes CES, Petersen AL de OA, et al. Advances in development of new treatment for leishmaniasis. Biomed Res Int. 2015;1–11. https://doi.org/10.1155/2015/815023

Reguera RM, Pérez-Pertejo Y, Gutiérrez-Corbo C, et al. Current and promising novel drug candidates against visceral leishmaniasis. Pure Appl Chem. 2019;91:1385–404. https://doi.org/10.1515/pac-2018-1102.

Article  CAS  Google Scholar 

Sundar S, Singh B. Emerging therapeutic targets for treatment of leishmaniasis. Expert Opin Ther Targets. 2018;22:467–86. https://doi.org/10.1080/14728222.2018.1472241.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pradhan S, Schwartz RA, Patil A, et al. Treatment options for leishmaniasis. Clin Exp Dermatol. 2022;47:516–21. https://doi.org/10.1111/ced.14919.

Article  CAS  PubMed  Google Scholar 

Maltezou HC. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol. 2010;1–8. https://doi.org/10.1155/2010/617521

Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis. 2002;15:593–8. https://doi.org/10.1097/00001432-200212000-00007.

Article  CAS  PubMed  Google Scholar 

Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother. 2004;10:307–15. https://doi.org/10.1007/s10156-004-0348-9.

Article  PubMed  Google Scholar 

Zazo H, Colino CI, Lanao JM. Current applications of nanoparticles in infectious diseases. J Control Release. 2016;224:86–102. https://doi.org/10.1016/j.jconrel.2016.01.008.

Article  CAS  PubMed  Google Scholar 

Mahajan S, Law, Aalinkeel, et al. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int J Nanomed. 2012;5301. https://doi.org/10.2147/IJN.S25871.

Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: Dose and response. J Glob Infect Dis. 2010;2:159. https://doi.org/10.4103/0974-777X.62886.

Article  PubMed  PubMed Central  Google Scholar 

Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21:2475–90. https://doi.org/10.1016/S0142-9612(00)00115-0.

Article  CAS  PubMed  Google Scholar 

Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm. 2009;379:201–9. https://doi.org/10.1016/j.ijpharm.2009.04.026.

Article  CAS  PubMed  Google Scholar 

Heurtault B, Saulnier P, Pech B, et al. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. 2002;19:875–80. https://doi.org/10.1023/A:1016121319668.

Article  CAS  PubMed  Google Scholar 

Gao W, Hu C-MJ, Fang RH, Zhang L. Liposome-like nanostructures for drug delivery. J Mater Chem B. 2013;1:6569. https://doi.org/10.1039/c3tb21238f

Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27:1372. https://doi.org/10.3390/molecules27041372.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6. https://doi.org/10.3389/fphar.2015.00286.

Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30:592–9. https://doi.org/10.1016/j.tips.2009.08.004.

Article  CAS  PubMed  Google Scholar 

Nsairat H, Khater D, Sayed U, et al. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8:e09394. https://doi.org/10.1016/j.heliyon.2022.e09394.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102. https://doi.org/10.1186/1556-276X-8-102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheikholeslami B, Lam NW, Dua K, Haghi M. Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate. Life Sci. 2022;300:120574. https://doi.org/10.1016/j.lfs.2022.120574.

Article  CAS  PubMed  Google Scholar 

Frolov VA, Shnyrova AV, Zimmerberg J. Lipid polymorphisms and membrane shape. Cold Spring Harb Perspect Biol. 2011;3:a004747–a004747. https://doi.org/10.1101/cshperspect.a004747.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;975. https://doi.org/10.2147/IJN.S68861.

Chowdhury DF. Pharmaceutical nanosystems: manufacture, characterization, and safety. In: Pharmaceutical sciences encyclopedia. New York: Wiley; 2010. pp 1–38.

Munye MM, Ravi J, Tagalakis AD, et al. Role of liposome and peptide in the synergistic enhancement of transfection with a lipopolyplex vector. Sci Rep. 2015;5:9292. https://doi.org/10.1038/srep09292.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garg T, Goyal AK. Liposomes: targeted and controlled delivery system. Drug Delivery Lett. 2014;4:62–71.

Article  CAS  Google Scholar 

Demel RA, De Kruyff B. The function of sterols in membranes. Biochimica et Biophysica Acta (BBA) - reviews on biomembranes. 1976;457:109–132. https://doi.org/10.1016/0304-4157(76)90008-3

Briuglia M-L, Rotella C, McFarlane A, Lamprou DA. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Transl Res. 2015;5:231–42. https://doi.org/10.1007/s13346-015-0220-8.

Article  CAS